Hong Kong stock movement | CUTIA-B (02487) rose more than 11% at the close, and the company is expected to welcome three major new products in the pipeline by 2025.

CUTIA-B (02487) rose over 11% in late trading, currently up 11.75%, priced at 5.8 Hong Kong dollars, with a transaction amount of 11.5499 million Hong Kong dollars.

Zhitong Finance03:55 ET

CUTIA-B: 2024 Annual Report

HKEXApr 22 08:45 ET · Announcements

Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%. The impact of China Securities Co.,Ltd.'s tariff policy on the Industry Chain of pharmaceuticals still has uncertainties.

Jinwu Finance | Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%, HBM HOLDINGS-B (02142) down 25.43%, CUTIA-B (02487) down 25.13%, Yiming Angke-B (01541) down 24.73%, CSTONE PHARMA-B (02616) down 24.68%, LAEKNA-B (02105) down 24.38%, WUXI BIO (02269) down 24.02%, JACOBIO-B (01167) down 23.72%, and WUXI XDC (02268) down 23.45%. According to multiple sources.

Jinwu Financial NewsApr 7 01:23 ET

Earnings Update: Cutia Therapeutics (HKG:2487) Just Reported And Analysts Are Trimming Their Forecasts

Simply Wall StMar 28 18:03 ET

Cutia Therapeutics (HKG:2487) Soars 26% But It's A Story Of Risk Vs Reward

Simply Wall StMar 26 19:03 ET

China International Capital Corp: Maintains CUTIA-B (02487) outperform industry rating and lowers Target Price to 9.31 HKD.

The bank believes that the subsequent dense pipeline launch is expected to contribute to performance growth, and is Bullish on the company's medium to long-term growth potential in becoming a skin management platform.

Zhitong FinanceMar 25 21:40 ET